7% Off
Myfortic180 mg
Novartis (Bangladesh) Ltd.
৳697.50
Add to cart
Origano DR180 mg
Tablet
By
Best PriceTk /
1
Alternatives
Price
Medicine overview
Indications of Origano DR 180 mg
Prophylaxis of organ rejection in kidney transplant: Origano DR 180 mg is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. It is indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant.
Theropeutic Class
Immunosuppressant
Pharmacology
Origano DR 180 mg delayed-release tablets are enteric coated formulation of mycophenolate sodium that delivers the active moiety Origano DR 180 mg.
Absorption
It is an immunosuppressive agent. It is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH).
Distribution
Therefore, it inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation to DNA. Origano DR 180 mg has cytostatic effects on lymphocytes.
Metabolism
It has been shown to prevent the occurrence of acute rejection of kidney and heart allotransplantation. It also decreases antibody production.
Dosage & Administration of Origano DR 180 mg
Dosage in adult kidney transplant patients
Dosage:The recommended dose of Origano DR 180 mg is 720 mg administered twice daily (1440 mg total daily dose)
Dosage in pediatric kidney transplant patients
Dosage:The recommended dose of Origano DR 180 mg in conversion (at least 6 months post-transplant) pediatric patients age 5 years and older is 400 mg/m2 body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily)
Notes:Pediatric patients with a BSA of 1.19 to 1.58 m2 may be dosed either with three Origano DR 180 mg 180 mg tablets, or one 180 mg tablet plus one 360 mg tablet twice daily (1080 mg daily dose). Patients with a BSA of >1.58 m2 may be dosed either with four Origano DR 180 mg 180 mg tablets, or two Origano DR 180 mg 360 mg tablets twice daily (1440 mg daily dose). Origano DR 180 mg tablets should be taken on an empty stomach, 1 hour before or 2 hours after food intake. Tablets should not be crushed, chewed, or cut prior to ingesting. The tablets should be swallowed whole in order to maintain the integrity of the enteric coating
| Condition | Dosage | Notes |
|---|---|---|
| Dosage in adult kidney transplant patients | The recommended dose of Origano DR 180 mg is 720 mg administered twice daily (1440 mg total daily dose) | |
| Dosage in pediatric kidney transplant patients | The recommended dose of Origano DR 180 mg in conversion (at least 6 months post-transplant) pediatric patients age 5 years and older is 400 mg/m2 body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily) | Pediatric patients with a BSA of 1.19 to 1.58 m2 may be dosed either with three Origano DR 180 mg 180 mg tablets, or one 180 mg tablet plus one 360 mg tablet twice daily (1080 mg daily dose). Patients with a BSA of >1.58 m2 may be dosed either with four Origano DR 180 mg 180 mg tablets, or two Origano DR 180 mg 360 mg tablets twice daily (1440 mg daily dose). Origano DR 180 mg tablets should be taken on an empty stomach, 1 hour before or 2 hours after food intake. Tablets should not be crushed, chewed, or cut prior to ingesting. The tablets should be swallowed whole in order to maintain the integrity of the enteric coating |
Dosage of Origano DR 180 mg
Dosage in adult kidney transplant patients
Dosage:The recommended dose of Origano DR 180 mg is 720 mg administered twice daily (1440 mg total daily dose)
Dosage in pediatric kidney transplant patients
Dosage:The recommended dose of Origano DR 180 mg in conversion (at least 6 months post-transplant) pediatric patients age 5 years and older is 400 mg/m2 body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily)
Notes:Pediatric patients with a BSA of 1.19 to 1.58 m2 may be dosed either with three Origano DR 180 mg 180 mg tablets, or one 180 mg tablet plus one 360 mg tablet twice daily (1080 mg daily dose). Patients with a BSA of >1.58 m2 may be dosed either with four Origano DR 180 mg 180 mg tablets, or two Origano DR 180 mg 360 mg tablets twice daily (1440 mg daily dose). Origano DR 180 mg tablets should be taken on an empty stomach, 1 hour before or 2 hours after food intake. Tablets should not be crushed, chewed, or cut prior to ingesting. The tablets should be swallowed whole in order to maintain the integrity of the enteric coating
| Condition | Dosage | Notes |
|---|---|---|
| Dosage in adult kidney transplant patients | The recommended dose of Origano DR 180 mg is 720 mg administered twice daily (1440 mg total daily dose) | |
| Dosage in pediatric kidney transplant patients | The recommended dose of Origano DR 180 mg in conversion (at least 6 months post-transplant) pediatric patients age 5 years and older is 400 mg/m2 body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily) | Pediatric patients with a BSA of 1.19 to 1.58 m2 may be dosed either with three Origano DR 180 mg 180 mg tablets, or one 180 mg tablet plus one 360 mg tablet twice daily (1080 mg daily dose). Patients with a BSA of >1.58 m2 may be dosed either with four Origano DR 180 mg 180 mg tablets, or two Origano DR 180 mg 360 mg tablets twice daily (1440 mg daily dose). Origano DR 180 mg tablets should be taken on an empty stomach, 1 hour before or 2 hours after food intake. Tablets should not be crushed, chewed, or cut prior to ingesting. The tablets should be swallowed whole in order to maintain the integrity of the enteric coating |
Interaction of Origano DR 180 mg
Caution should be exercised with concomitant administration of Antacids, Azathioprine, Cyclosporin, Rifampin, Sevelamer, Cholestyramine, Acyclovir, Metronidazole, Hormonal contraceptives as these medicines may decrease Origano DR 180 mg concentration.
Contraindications
Origano DR 180 mg delayed-release tablets and Mycophenolate mofetil tablets and capsules should not be used interchangeably without physician supervision because the rate of absorption following the administration of these two products is not equivalent.
Side Effects of Origano DR 180 mg
The most common adverse reactions (≥20%) associated with the administration of Origano DR 180 mg are anemia, leukopenia, constipation, diarrhea, vomiting, dyspepsia, urinary tract infection, CMV infection, insomnia, and postoperative pain.
Pregnancy & Lactation
Pregnancy Category D. Can cause fetal harm.Lactation: Discontinue Origano DR 180 mg or discontinue nursing while on treatment or within 6 weeks after stopping therapy. Take into consideration the importance of the drug to the mother.
Precautions & Warnings
Origano DR 180 mg tablets are used with caution because it-
Can cause embryofetal toxicity
Can increase new or reactive viral infections
Can cause blood dyscrasias including pure red cell aplasia
Can cause serious GI tract complications (gastrointestinal bleeding, perforations and ulcers)
May increase the risk of developing lymphomas and other malignancies, particularly of the skin
Use of live vaccine should be avoided during treatment with Origano DR 180 mg
Overdose Effects of Origano DR 180 mg
No data are available with regard to overdose.
Storage Conditions
Store at 25° C and Keep out of reach of children.
Drug Classes
Immunosuppressant
Mode Of Action
Origano DR 180 mg delayed-release tablets are enteric coated formulation of mycophenolate sodium that delivers the active moiety Origano DR 180 mg. It is an immunosuppressive agent. It is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). Therefore, it inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation to DNA. Origano DR 180 mg has cytostatic effects on lymphocytes. It has been shown to prevent the occurrence of acute rejection of kidney and heart allotransplantation. It also decreases antibody production.
Pregnancy
Pregnancy Category D. Can cause fetal harm.Lactation: Discontinue Origano DR 180 mg or discontinue nursing while on treatment or within 6 weeks after stopping therapy. Take into consideration the importance of the drug to the mother.
Frequently Asked Questions
What is Origano DR 180 mg used for?
Prophylaxis of organ rejection in kidney transplant: Mycophenolic acid is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. It is indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant.
What is the dosage of Origano DR 180 mg?
Dosage in adult kidney transplant patients: The recommended dose of Mycophenolic acid is 720 mg administered twice daily (1440 mg total daily dose).Dosage in pediatric kidney transplant patients: The recommended dose of Mycophenolic acid in conversion (at least 6 months post-transplant) pediatric patients age 5 years and older is 400 mg/m2 body surface area (BSA) administered twice daily (up to a …
What are the side effects of Origano DR 180 mg?
The most common adverse reactions (≥20%) associated with the administration of Mycophenolic acid are anemia, leukopenia, constipation, diarrhea, vomiting, dyspepsia, urinary tract infection, CMV infection, insomnia, and postoperative pain.
Who should not take Origano DR 180 mg?
Mycophenolic acid delayed-release tablets and Mycophenolate mofetil tablets and capsules should not be used interchangeably without physician supervision because the rate of absorption following the administration of these two products is not equivalent.
What precautions should be taken with Origano DR 180 mg?
Mycophenolic acid tablets are used with caution because it- Can cause embryofetal toxicity Can increase new or reactive viral infections Can cause blood dyscrasias including pure red cell aplasia Can cause serious GI tract complications (gastrointestinal bleeding, perforations and ulcers) May increase the risk of developing lymphomas and other malignancies, particularly of the skin Use of live vac…
Is Origano DR 180 mg safe during pregnancy and breastfeeding?
Pregnancy Category D. Can cause fetal harm.Lactation: Discontinue Mycophenolic acid or discontinue nursing while on treatment or within 6 weeks after stopping therapy. Take into consideration the importance of the drug to the mother.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.